Caliway Selected to Present Preclinical Data on CBL-514 in Combination with GLP-1R Therapy at ECO 2026
NEW TAIPEI CITY -- Caliway Biopharmaceuticals, a clinical-stage biopharmaceutical company advancing innovative small-molecule therapies in aesthetic medicine, metabolic diseases, and other unmet medical needs, today announced that the latest preclinical data on CBL-514 in combination with GLP-1R agonists has been selected for oral presentation at the 33rd European Congress on Obesity (ECO 2026), which will take place in Istanbul, Türkiye, from May 12 to 15, 2026.
Expert Insights on Obesity Medicine
The presentation will be delivered by Arya M. Sharma, MD, a globally recognized authority in obesity medicine and a scientific advisor to Caliway, who will provide scientific perspectives on the potential value of CBL-514 in expanding from aesthetic fat reduction into the obesity treatment field. Dr. Sharma is a pioneer in recognizing obesity as a chronic disease and is also the creator of the widely adopted Edmonton Obesity Staging System (EOSS). In addition, he has been invited to serve as a scientific advisor and speaker in obesity medicine for multinational pharmaceutical companies, including Novo Nordisk and Eli Lilly.
Addressing the Limitations of Current Therapies
The selection of Caliway's preclinical data for oral presentation at ECO not only reflects expert recognition of CBL-514's differentiated adipocyte-apoptosis mechanism and advantages, but also highlights its translational potential demonstrated in preclinical studies. It may offer a promising new scientific direction for addressing important limitations of current weight-loss therapies that primarily rely on appetite suppression, including post-discontinuation weight regain and deterioration in body composition.
About the European Congress on Obesity (ECO)
Organized by the European Association for the Study of Obesity (EASO), ECO is one of the most influential international scientific meetings in the fields of obesity and metabolic disease. Each year, it brings together nearly 4,000 experts and scholars from more than 70 countries, while major multinational pharmaceutical companies also send senior leadership to attend. ECO serves as an important platform for sharing the latest advances in weight-loss therapies, including incretin-based therapies, treatment guidelines, and emerging research findings.
The title of the presentation is: "CBL-514 An Adipocyte-Apoptosis Agent Enhances GLP-1 Induced Weight Loss and Attenuates Weight Regain In Diet-Induced Obese Rats."
Synergistic Potential of CBL-514 and GLP-1R
After Caliway first shared OI23 data with industry experts during the European Association for the Study of Diabetes (EASD) last year, the findings attracted strong interest from multiple international pharmaceutical companies. At ECO 2026, Dr. Sharma is expected to further discuss the potential synergistic mechanism generated by the combination of CBL-514 and GLP-1R therapy.
About CBL-514
CBL-514, a 505(b)(1) and first-in-class small-molecule drug developed by Caliway, is the world's first injectable lipolysis drug that induces adipocyte apoptosis to reduce subcutaneous fat in targeted areas.
